AstraZeneca remembers roots with $135 million Swedish spend

28 August 2024

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) is making a new $135 million investment in its biologics facility in Södertälje, Sweden.

This constitutes the largest single investment in the facility since the 2021 opening of the Sweden Biomanufacturing Center, which lies in the town, a few miles from capital Stockholm.

The company has stressed that this project will create new job opportunities and underline the company's commitment to economic growth and job creation in the region. It also reflects the importance attached to biologics in AstraZeneca's R&D activities as it seeks to develop medicines for the future.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK